CXCL13 and in situ carcinoma: YKL-40 and CXCL13 (a chemokine implicated in B cell aggregates that develop in the inflamed meninges of PMS patients (71)) showed the most consistent results, with increased CSF levels at baseline in CIS subjects who received a MS diagnosis during follow-up, as compared with those who did not.